Gene Security Network in race for prenatal test

Gene Security Network’s race to develop safer, more accurate prenatal test is all business for Matt Rabinowitz — and it’s personal.
A relative of Rabinowitz, Gene Security Network’s CEO, took a blood test for the likelihood of Down’s syndrome in her unborn baby and was deemed low risk, but she gave birth to a child with the disease. The child died six days later.
The probability of such inaccurate results could shrink if Gene Security Network and a handful of other prenatal diagnostics developers continue their pace toward new tests. But GSN, like San Carlos-based Verinata Health and well-known Sequenom Inc., face an uncertain future of regulation that could restrain investors.